You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Baxter
McKinsey
Merck

Last Updated: December 1, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Quizartinib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Quizartinib?

Quizartinib is an investigational drug.

There have been 28 clinical trials for Quizartinib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Daiichi Sankyo Co., Ltd., Daiichi Sankyo Inc., and National Cancer Institute (NCI).

There are twenty-five US patents protecting this investigational drug and two hundred and twenty-four international patents.

Recent Clinical Trials for Quizartinib
TitleSponsorPhase
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsNational Cancer Institute (NCI)Phase 1/Phase 2
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsM.D. Anderson Cancer CenterPhase 1/Phase 2
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic ImpairmentDaiichi Sankyo Co., Ltd.Phase 1

See all Quizartinib clinical trials

Clinical Trial Summary for Quizartinib

Top disease conditions for Quizartinib
Top clinical trial sponsors for Quizartinib

See all Quizartinib clinical trials

US Patents for Quizartinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Quizartinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Quizartinib   Start Trial Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Quizartinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Quizartinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Quizartinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Quizartinib   Start Trial CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Quizartinib

Drugname Country Document Number Estimated Expiration Related US Patent
Quizartinib Argentina AR109919 2036-10-10   Start Trial
Quizartinib Australia AU2017342022 2036-10-10   Start Trial
Quizartinib Brazil BR112019007144 2036-10-10   Start Trial
Quizartinib Canada CA3039760 2036-10-10   Start Trial
Quizartinib Chile CL2019000941 2036-10-10   Start Trial
Quizartinib China CN110382494 2036-10-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Baxter
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.